DCP is pleased to announce the inaugural cohort of the DCP Early Career Scientist Spotlight Research Seminar Series to begin in 2024. This new series of public seminars will recognize nominated early career scientists who are advancing prevention research within the areas supported by DCP.

Email NCIDCPworkforce if you have questions about the series.

Worta McCaskill-Stevens, M.D.: An Appreciation for a Driving Force in Cancer Prevention and Addressing Cancer Disparities

Worta McCaskill-Stevens, M.D., former director of the NCI Community Oncology Research Program (NCORP) who worked in DCP for 25 years, and a tireless champion of addressing cancer disparities, passed away peacefully on November 15, 2023. Her legacy continues in NCORP and beyond.

Read the appreciation.

NCI PREVENT Cancer Program - Seeking Innovative Ideas in Cancer Prevention & Interception: Applications Due January 8, 2024

The NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program that supports the preclinical development of innovative interventions and predictive biomarkers for cancer prevention and interception towards clinical applications in high-risk populations. All interested researchers with innovative ideas in precision cancer prevention are encouraged to apply.

Deadline: January 8, 2024

PREVENT’s current research priority areas are:

• Immunoprevention (e.g., vaccines for cancers associated or not associated with infectious agents, immunomodulatory agents)
• Chemoprevention (e.g., novel mechanisms, anti-inflammatory approaches, drug repurposing, toxicity reduction strategies)
• Clinically translatable, response-predictive biomarkers (e.g., biomarkers predictive for tumor development and progression, biomarkers useful for monitoring cancer prevention efficacy)

For more information, a list of current projects, and the application visit the PREVENT web page.

Thursday, December 7
8:30 a.m. - 4:00 p.m. ET
Join the meeting live

This will be the third of three public meetings hosted by the President’s Cancer Panel on Reducing Cancer Care Inequities: Leveraging Technology to Enhance Patient Navigation. The presentations and discussions from all three meetings will inform the Panel's recommendations in a formal report to the President of the United States.

Immune Interception Approaches for Individuals at Risk for Pancreatic Cancer

Wednesday, December 13
1:00 - 2:00 p.m. ET
Advanced registration is required

Elizabeth M. Jaffee, M.D., professor of oncology and deputy director of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, will give a talk on cancer prevention, interception, and immuno-oncology, as part of the NCI DCP Immunology Interest Group Seminar Series. Dr. Jaffee is an internationally recognized expert in cancer immunology and pancreatic cancer.

NCI invites applications from organizations that seek to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/interception, cancer-related health behaviors, screening, early detection, health care delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors.

PAR-22-173 (R34 Clinical Trials Optional)
PAR-22-174 (U34 Clinical Trials Optional)

Expires: September 8, 2025

NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers

This program aims to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. Postdoctoral researchers in the scientific areas of cancer control, cancer prevention, and cancer data sciences are especially encouraged to work with their institutions to apply.

PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed)
PAR-23-287 (K99/R00 - Independent Clinical Trial Required)
PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required)

Expires: October 15, 2026